小分子抑制剂与生物制剂治疗甲银屑病:系统评价与网状Meta分析
结果显示,10-16周时托法替布对甲评分改善最优,24-26周时依奇珠单抗最优;NAPSI 100%改善方面依奇珠单抗疗效最佳。
要点
- 托法替布在10-16周对甲银屑病评分改善最优。
- 依奇珠单抗在24-26周对甲评分改善最优。
- 依奇珠单抗在NAPSI 100%改善方面疗效最佳。
核心结论
- 托法替布和依奇珠单抗分别在小分子抑制剂与生物制剂治疗甲银屑病的10-16周和24-26周表现出最佳疗效。
主要发现
- 托法替布在10-16周甲评分改善的加权均数差为56.67(95%CI 35.87-77.48)。
- 依奇珠单抗在24-26周甲评分改善的加权均数差为59.40(95%CI 45.87-72.93)。
- 依奇珠单抗在NAPSI 100%改善的比值比为2.98(95%CI 1.74-5.10)。
临床怎么用
- 临床可参考疗程选择:短期(10-16周)优先考虑托法替布,中长期(24-26周)优先考虑依奇珠单抗。
局限性
- 符合条件的数据不足,且缺乏长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Various systemic immunomodulating therapies have been investigated to treat nail psoriasis, but the efficacy remains unclear. OBJECTIVE: To perform a systematic review and network meta-analysis to evaluate the efficacy of small molecule inhibitors and biologics in treating nail psoriasis. METHODS: Eligible studies in online databases were identified until March 10, 2020. To assess the efficacy of small molecule inhibitors and biologics, network meta-analyses with surface under the cumulative ranking curve of improvement in nail score at 10 to 16 and at 24 to 26 weeks, as well as 100% improvement of Nail Psoriasis Severity Index (NAPSI), were performed. RESULTS: Thirty-nine studies with a total of 13 treatment arms involving 15,673 patients with nail psoriasis were included. An network meta-analysis showed that tofacitinib (weighted mean difference, 56.67; 95% confidence interval [CI], 35.87-77.48) and ixekizumab (weighted mean difference, 59.40; 95% CI, 45.87-72.93) presented the most improvement of nail score at 10 to 16 weeks and 24 to 26 weeks, respectively. For 100% improvement of the Nail Psoriasis Severity Index, ixekizumab showed the best efficacy among all treatments (odds ratio, 2.98; 95% CI, 1.74-5.10). LIMITATIONS: Insufficiency of eligible data and no long-term follow-up data. CONCLUSION: Tofacitinib and ixekizumab presented the best efficacy for treating nail psoriasis in 10 to 16 weeks and 24 to 26 weeks, respectively.
引用
- Huang IH, Wu PC, Yang TH, et al. Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis. J Am Acad Dermatol. 2021. PMID: 33482253. doi:10.1016/j.jaad.2021.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。